Since CytomX Therapeutics Inc. (NASDAQ:CTMX) and Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation of both companies.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics Inc.	59.50M	7.82	84.60M	-1.93	0.00
Tonix Pharmaceuticals Holding Corp.	N/A	0.00	29.36M	-28.85	0.00

Table 1 showcases the gross revenue, earnings per share (EPS) and valuation of CytomX Therapeutics Inc. and Tonix Pharmaceuticals Holding Corp.

Profitability

Table 2 represents CytomX Therapeutics Inc. (NASDAQ:CTMX) and Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)’s return on assets, return on equity and net margins.

	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics Inc.	-142.18%	-48.5%	-9.4%
Tonix Pharmaceuticals Holding Corp.	0.00%	-131.9%	-116.8%

Risk & Volatility

CytomX Therapeutics Inc.’s volatility measures that it’s 28.00% less volatile than Standard and Poor’s 500 due to its 0.72 beta. Tonix Pharmaceuticals Holding Corp. has a 1.87 beta and it is 87.00% more volatile than Standard and Poor’s 500.

Liquidity

The current Quick Ratio of CytomX Therapeutics Inc. is 5.5 while its Current Ratio is 5.5. Meanwhile, Tonix Pharmaceuticals Holding Corp. has a Current Ratio of 6.8 while its Quick Ratio is 6.8. Tonix Pharmaceuticals Holding Corp. is better positioned to pay off its short-term and long-term debts than CytomX Therapeutics Inc.

Analyst Ratings

The following table delivered below contains the ratings and recommendations for CytomX Therapeutics Inc. and Tonix Pharmaceuticals Holding Corp.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
CytomX Therapeutics Inc.	0	0	1	3.00
Tonix Pharmaceuticals Holding Corp.	0	0	0	0.00

CytomX Therapeutics Inc. has a 142.25% upside potential and an average price target of $25.

Insider and Institutional Ownership

CytomX Therapeutics Inc. and Tonix Pharmaceuticals Holding Corp. has shares held by institutional investors as follows: 86.7% and 11.4%. Insiders held roughly 0.2% of CytomX Therapeutics Inc.’s shares. Comparatively, 4.73% are Tonix Pharmaceuticals Holding Corp.’s share held by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
CytomX Therapeutics Inc.	-44.83%	-37.75%	-25.56%	-54.65%	-64.48%	-30%
Tonix Pharmaceuticals Holding Corp.	-2.63%	-4.64%	-51.32%	-82.04%	-94.61%	-15.91%

For the past year CytomX Therapeutics Inc. was more bearish than Tonix Pharmaceuticals Holding Corp.

Summary

CytomX Therapeutics Inc. beats Tonix Pharmaceuticals Holding Corp. on 6 of the 10 factors.

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops novel class of antibody therapeutics based on its Probody technology platform that address clinically-validated cancer targets in immuno-oncology, such as PD-L1, as well as novel targets, comprising CD-166. Its other product candidates in preclinical development include CX-2029, CD71, CTLA-4, and CX-188. In addition, the company has strategic collaborations with AbbVie Ireland Unlimited Company, Bristol-Myers Squibb Company, ImmunoGen, Inc., M D Anderson Cancer Center, Pfizer Inc., and The University of Texas to develop Probody therapeutics. It also has a strategic collaboration with Amgen Inc. to co-develop a CytomX Probody T-cell engaging bispecific against the epidermal growth factor receptor, a validated oncology target expressed on multiple human cancer types. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Tonix Pharmaceuticals Holding Corp. engages in developing pharmaceutical and biological products to address public health challenges. Its lead product candidate, TNX-102 SL or Tonmya, designed as a bedtime treatment for posttraumatic stress disorder (PTSD), which is in Phase 3 study in the military-related PTSD population. The company is also developing TNX-601 (tianeptine oxalate), a clinical candidate at pre-IND (investigational new drug) application stage, designed as a daytime treatment for posttraumatic stress disorder (PTSD); and TNX-801, a live synthetic version of horsepox virus, at the pre-IND application stage. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in New York, New York.